Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2002-07-22
2004-03-02
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C558S426000
Reexamination Certificate
active
06699903
ABSTRACT:
AREA OF THE INVENTION
This invention relates to the preparation of a monohydrate of the lithium salt of cis 4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate, and the hydrate per se.
BACKGOUND OF THE INVENTION
Cyclic nucleotide phosphodiesterases (PDEs) represent a family of enzymes that hydrolyze the ubiquitous intracellular second messengers, adenosine 3′,5′-monophosphate (cAMP) and guanosine 3′,5′-monophosphate (cGMP) to their corresponding inactive 5′-monophosphate metabolites. At least ten distinct classes of PDE isozymes are believed to exist, each possessing unique physical and kinetic characteristics and each representing a product of a different gene family. These are distinguished using Arabic numerals 1-10.
A new approach toward improving the side effect profile of PDE inhibitors is to design a new generation of compounds that inhibit only a single PDE isozyme, i.e., the PDE isozyme that predominates in the tissue of cell of interest. The predominate cAMP PDE isozyme in immune and inflammatory cells is PDE4. It is also a major regulator of cAMP content in airway smooth muscle. Thus, selective inhibition of PdE4 elevates cAMP content in immune and inflammatory cells, as well as in airway smooth muscle. This leads to anti-inflammatory effects as well as bronchodilation. One or both of these therapeutic actions are useful in treating a variety of diseases, including, but not limited to asthma and COPD. PDE4 inhibitors, particularly PDE4-specific inhibitors are useful also in treating other diseases in the area of inflammation, (e.g., asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, rheumatoid arthritis), affects related to tumor necrosis factor and to cognition impairment (e.g., multi-infarct dementia, cognitive dysfunction, or stroke). This invention relates to a compound that is better tolerated than previous PDE4 inhibitors, namely cis-4-cyano-4-[3-(cyclopentyloxy)-4-metboxyphenyl]cyclohexane-1-carboxylic acid. More specifically this invention provides the hydrate of the lithium salt of this acid.
REFERENCES:
patent: 5552438 (1996-09-01), Christensen, IV
patent: 5602157 (1997-02-01), Christensen, IV
Kanagy James M.
Kinzig Charles M.
McKane Joseph K.
Saeed Kamal
SmithKline Beecham Corporation
LandOfFree
Monohydrate of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monohydrate of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monohydrate of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3208013